SGLT-2 inhibitors - An assessment of the German oral therapeutic landscape for people with type 2 diabetes

被引：0

作者：

Aberle, Jens ^{[1
]}

Blueher, Matthias ^{[2
]}

Laudes, Matthias ^{[3
]}

Merkel, Martin ^{[4
]}

Sandow, Petra ^{[5
]}

机构：

[1] Univ Klinikum Hamburg Eppendorf, Endokrinol & Diabetol, Univ Adipositaszentrum Hamburg, Hamburg, Germany

[2] Univ Med Leipzig, Helmholtz Inst Metab Adipositas & Gefassforsch HI, Leipzig, Germany

[3] Univ Klinikum Schleswig Holstein, Med Klin 1, Kiel, Germany

[4] Endokrinol Hamburg, Internist Endokrinol Diabetol, Hamburg, Germany

[5] Praxis, Allgemeinmed, Berlin, Germany

来源：

DIABETOLOGIE UND STOFFWECHSEL | 2025年 / 20卷 / 01期

关键词：

SGLT2; type; 2; diabetes; therapy; prevention; comparison; POST-HOC ANALYSES; CARDIOVASCULAR OUTCOMES; KIDNEY-DISEASE; DAPAGLIFLOZIN; MELLITUS; PREVENTION; EFFICACY; PLACEBO; SAFETY;

D O I：

10.1055/a-2549-1472

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

As numerous extensive studies have shown, SGLT2 inhibitors not only have beneficial effects on glucose metabolism, but also have a pronounced protective effect on the heart and kidneys. This class of drugs therefore plays an important role in the primary and secondary prevention of diabetes-associated comorbidities. Based on the evidence for SGLT2 inhibitors, guidelines recommend their early use in people with type 2 diabetes being at high risk of cardiovascular and/or renal events. However, prescription data show that these recommendations are currently not implemented and that significantly more people with type 2 diabetes could benefit from organ-protective therapy. Therefore, the aim of this review is to present the value of SGLT2 inhibitors in comparison to other oral therapeutic approaches for the treatment of type 2 diabetes.

引用

页码：59 / 70

页数：12

共 92 条

[41]

Heerspink HJL, 2020, LANCET DIABETES ENDO, V8, P27, DOI 10.1016/S2213-8587(19)30384-5

[42]

Hellman M., SGLT2 INHIBITOREN FA

[43] Empagliflozin in Patients with Chronic Kidney Disease [J].

Herrington, William G. ;

Staplin, Natalie ;

Wanner, Christoph ;

Green, Jennifer B. ;

Hauske, Sibylle J. ;

Emberson, Jonathan R. ;

Preiss, David ;

Judge, Parminder ;

Mayne, Kaitlin J. ;

Ng, Sarah Y. A. ;

Sammons, Emily ;

Zhu, Doreen ;

Hill, Michael ;

Stevens, Will ;

Wallendszus, Karl ;

Brenner, Susanne ;

Cheung, Alfred K. ;

Liu, Zhi-Hong ;

Li, Jing ;

Hooi, Lai Seong ;

Liu, Wen ;

Kadowaki, Takashi ;

Nangaku, Masaomi ;

Levin, Adeera ;

Cherney, David ;

Maggioni, Aldo P. ;

Pontremoli, Roberto ;

Deo, Rajat ;

Goto, Shinya ;

Rossello, Xavier ;

Tuttle, Katherine R. ;

Steubl, Dominik ;

Petrini, Michaela ;

Massey, Dan ;

Eilbracht, Jens ;

Brueckmann, Martina ;

Landray, Martin J. ;

Baigent, Colin ;

Haynes, Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (02) :117-127

[44] 10-year follow-up of intensive glucose control in type 2 diabetes [J].

Holman, Rury R. ;

Paul, Sanjoy K. ;

Bethel, M. Angelyn ;

Matthews, David R. ;

Neil, H. Andrew W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1577-1589

[45] Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study [J].

Hougen, Ingrid ;

Whitlock, Reid H. ;

Komenda, Paul ;

Rigatto, Claudio ;

Clemens, Kristin K. ;

Tangri, Navdeep .

BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (02)

[46] Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure [J].

James, Stefan ;

Erlinge, David ;

Storey, Robert F. ;

Mcguire, Darren K. ;

de Belder, Mark ;

Eriksson, Niclas ;

Andersen, Kasper ;

Austin, David ;

Arefalk, Gabriel ;

Carrick, David ;

Hofmann, Robin ;

Hoole, Stephen P. ;

Jones, Daniel A. ;

Lee, Kelvin ;

Tygesen, Hans ;

Johansson, Peter A. ;

Langkilde, Anna Maria ;

Ridderstrale, Wilhelm ;

Parvaresh Rizi, Ehsan ;

Deanfield, John ;

Oldgren, Jonas ;

DAPA MI Investigators .

NEJM EVIDENCE, 2024, 3 (02)

[47] Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER [J].

Jhund, Pardeep S. ;

Kondo, Toru ;

Butt, Jawad H. ;

Docherty, Kieran F. ;

Claggett, Brian L. ;

Desai, Akshay S. ;

Vaduganathan, Muthiah ;

Gasparyan, Samvel B. ;

Bengtsson, Olof ;

Lindholm, Daniel ;

Petersson, Magnus ;

Langkilde, Anna Maria ;

de Boer, Rudolf A. ;

DeMets, David ;

Hernandez, Adrian F. ;

Inzucchi, Silvio E. ;

Kosiborod, Mikhail N. ;

Kober, Lars ;

Lam, Carolyn S. P. ;

Martinez, Felipe A. ;

Sabatine, Marc S. ;

Shah, Sanjiv J. ;

Solomon, Scott D. ;

McMurray, John J. V. .

NATURE MEDICINE, 2022, 28 (09) :1956-+

[48]

Kalra Sanjay, 2014, Indian J Endocrinol Metab, V18, P597, DOI 10.4103/2230-8210.139206

[49] Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data [J].

Khunti, Kamlesh ;

Kosiborod, Mikhail ;

Kim, Dae Jung ;

Kohsaka, Shun ;

Lam, Carolyn S. P. ;

Goh, Su-Yen ;

Chiang, Chern-En ;

Shaw, Jonathan E. ;

Cavender, Matthew A. ;

Tangri, Navdeep ;

Franch-Nadal, Josep ;

Holl, Reinhard W. ;

Jorgensen, Marit E. ;

Norhammar, Anna ;

Eriksson, Johan G. ;

Zaccardi, Francesco ;

Karasik, Avraham ;

Magliano, Dianna J. ;

Thuresson, Marcus ;

Chen, Hungta ;

Wittbrodt, Eric ;

Bodegard, Johan ;

Surmont, Filip ;

Fenici, Peter .

CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)

[50] Position statement: surgery and diabetes mellitus (Update 2023) [J].

Kietaibl, Antonia-Therese ;

Huber, Joakim ;

Clodi, Martin ;

Abrahamian, Heidemarie ;

Ludvik, Bernhard ;

Fasching, Peter .

WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 (SUPPL 1) :256-271

← 1 2 3 4 5 6 7 8 9 10 →